Valuation: Entrada Therapeutics, Inc.

Market Cap 159M 142M 131M 118M 221M 15.06B 226M 1.56B 626M 7.92B 595M 583M 24.99B P/E 2026 *
-1.1x
P/E 2027 * -1.22x
Enterprise Value 129M 115M 106M 95.94M 179M 12.2B 183M 1.26B 507M 6.42B 482M 472M 20.24B EV / Sales 2026 *
10.6x
EV / Sales 2027 * -5.27x
Free-Float
85.81%
Yield 2026 *
-
Yield 2027 * -
1 day+0.68%
1 week+0.45%
Current month-30.24%
1 month-30.24%
3 months-34.56%
6 months-67.19%
Current year-56.91%
1 week 4.26
Extreme 4.255
5.07
1 month 4.11
Extreme 4.1092
6.36
Current year 4.11
Extreme 4.1092
16.45
1 year 4.11
Extreme 4.1092
16.45
3 years 4.11
Extreme 4.1092
21.79
5 years 4.11
Extreme 4.1092
36.85
10 years 4.11
Extreme 4.1092
36.85
Manager TitleAgeSince
Chief Executive Officer 50 2017-07-31
Director of Finance/CFO 47 2020-10-31
President 56 2023-12-31
Director TitleAgeSince
Director/Board Member 50 2017-07-31
Chairman 45 2020-11-30
Director/Board Member 67 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
9/9/26
MPM BioImpact LLC
SellCompany -28,837 0.0741%
9/3/26
MPM BioImpact LLC
SellCompany -32,263 0.0829%
Change 5-day change 1-year change 3-year change Capi.($)
+3.18%+0.45%-35.80%-71.18% 159M
-0.62%+0.50%+33.92%+60.07% 64.38B
+0.35%+3.20%+14.92%+84.55% 56.16B
+0.53%+1.96%+15.37%+106.81% 54.16B
-2.91%-4.54%+23.19%+50.52% 45.33B
-0.32%-2.13%+19.90%+98.04% 42.25B
+0.53%+2.22%+224.67%+941.61% 40.78B
+3.27%+47.96%+112.67%+96.48% 33.8B
+1.22%-1.39%+13.92%+46.95% 32.25B
-1.29%-1.72%+21.00%-6.85% 23.57B
Average +0.09%+3.55%+44.38%+140.70% 39.28B
Weighted average by Cap. -0.05%+3.64%+50.03%+162.50%

Financials

2026 *2027 *
Net sales 12.17M 10.9M 10.03M 9.08M 16.98M 1.16B 17.3M 120M 48M 608M 45.67M 44.7M 1.92B 22.86M 20.48M 18.84M 17.07M 31.9M 2.17B 32.5M 225M 90.17M 1.14B 85.81M 83.98M 3.6B
Net income -174M -156M -144M -130M -243M -16.56B -248M -1.71B -688M -8.71B -654M -640M -27.46B -184M -165M -152M -138M -257M -17.51B -262M -1.81B -727M -9.21B -692M -677M -29.05B
Net Debt -30.12M -26.98M -24.82M -22.49M -42.03M -2.86B -42.82M -296M -119M -1.5B -113M -111M -4.74B -279M -250M -230M -208M -389M -26.5B -397M -2.74B -1.1B -13.94B -1.05B -1.03B -43.96B
Projected Income Statement - Annual - Entrada Therapeutics, Inc.
Logo Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
Employees
152
Date Price Change Volume
26-10-30 US$4.430 +0.68% 199,283
26-10-29 US$4.400 -9.09% 479,056
26-10-28 US$4.840 +9.75% 409,095
26-10-27 US$4.410 -7.16% 413,454
26-10-26 US$4.750 +7.71% 617,087
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Entrada Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.400USD
Average target price
19.00USD
Spread / Average Target
+331.82%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Entrada Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. TRDA Stock